在一个大型多机构队列中界定家族史对高级别前列腺癌检出的影响
这项多中心研究纳入2006至2019年在北美和欧洲12个中心接受前列腺活检的男性,评估家族史与高级别前列腺癌(Gleason分级分组≥2)风险的关系。一级亲属前列腺癌家族史与高级别前列腺癌风险升高相关(OR 1.77,95%CI 1.57-2.00,p<0.001,RR=1.40),二级亲属前列腺癌和一级亲属乳腺癌家族史亦相关;家族史效应不因PSA而异,但因年龄而异。
要点
- 一级亲属前列腺癌家族史者高级别前列腺癌风险升高(OR 1.77,95%CI 1.57-2.00,p<0.001,RR=1.40)。
- 二级亲属前列腺癌家族史OR 1.38(95%CI 1.07-1.77,p=0.011,RR=1.22)。
- 一级亲属乳腺癌家族史OR 1.30(95%CI 1.01-1.67,p=0.040,RR=1.18)。
核心结论
- 有活检指征且伴前列腺癌或乳腺癌家族史的男性,其高级别前列腺癌风险中度升高,且独立于其他危险因素。
研究设计与样本
- 多中心研究,纳入2006至2019年在北美和欧洲12个中心接受前列腺活检的男性。
- 所有中心记录一级亲属前列腺癌家族史,其中4个中心额外记录受累亲属数量、二级亲属前列腺癌及乳腺癌家族史等详细数据。
- 一级亲属前列腺癌家族史数据 available 于15799名男性,更详细家族史数据 available 于4617名男性(两队列中位年龄均为65岁)。
- 采用多变量逻辑回归评估高级别(Gleason分级分组≥2)前列腺癌的比值比。
主要发现
- 一级亲属前列腺癌家族史者高级别前列腺癌的校正OR为1.77(95%CI 1.57-2.00,p<0.001,RR=1.40)。
- 二级亲属前列腺癌家族史者OR为1.38(95%CI 1.07-1.77,p=0.011,RR=1.22)。
- 一级亲属乳腺癌家族史者OR为1.30(95%CI 1.01-1.67,p=0.040,RR=1.18)。
- 交互作用分析显示家族史效应不因前列腺特异性抗原(PSA)而异,但因年龄而异。
局限性
- 本研究受限于种族和既往阴性活检数据的缺失。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of high-grade prostate cancer, given a family history of cancer, has been described in the general population, but not among men selected for prostate biopsy in an international cohort. OBJECTIVE: To estimate the risk of high-grade prostate cancer on biopsy based on a family history of cancer. DESIGN, SETTING, AND PARTICIPANTS: This is a multicenter study of men undergoing prostate biopsy from 2006 to 2019, including 12 sites in North America and Europe. All sites recorded first-degree prostate cancer family histories; four included more detailed data on the number of affected relatives, second-degree relatives with prostate cancer, and breast cancer family history. OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable logistic regressions evaluated odds of high-grade (Gleason grade group ≥2) prostate cancer. Separate models were fit for family history definitions, including first- and second-degree prostate cancer and breast cancer family histories. RESULTS AND LIMITATIONS: A first-degree prostate cancer family history was available for 15 799 men, with a more detailed family history for 4617 (median age 65 yr, both cohorts). Adjusted odds of high-grade prostate cancer were 1.77 times greater (95% confidence interval [CI] 1.57-2.00, p < 0.001, risk ratio [RR] = 1.40) with first-degree prostate cancer, 1.38 (95% CI 1.07-1.77, p = 0.011, RR = 1.22) for second-degree prostate cancer, and 1.30 (95% CI 1.01-1.67, p = 0.040, RR = 1.18) for first-degree breast cancer family histories. Interaction terms revealed that the effect of a family history did not differ based on prostate-specific antigen but differed based on age. This study is limited by missing data on race and prior negative biopsy. CONCLUSIONS: Men with indications for biopsy and a family history of prostate or breast cancer can be counseled that they have a moderately increased risk of high-grade prostate cancer, independent of other risk factors. PATIENT SUMMARY: In a large international series of men selected for prostate biopsy, finding a high-grade prostate cancer was more likely in men with a family history of prostate or breast cancer.
引用
- Clements MB, Vertosick EA, Guerrios-Rivera L, et al. Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort. Eur Urol. 2021. PMID: 34980493. doi:10.1016/j.eururo.2021.12.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。